Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Prelude Therapeutics (PRLD) Return on Sales (2024 - 2025)

Prelude Therapeutics' Return on Sales history spans 2 years, with the latest figure at 16.09% for Q4 2025.

  • For Q4 2025, Return on Sales fell 763.0% year-over-year to 16.09%; the TTM value through Dec 2025 reached 16.09%, up 387.0%, while the annual FY2025 figure was 8.61%, 1135.0% up from the prior year.
  • Return on Sales for Q4 2025 was 16.09% at Prelude Therapeutics, down from 3.14% in the prior quarter.
  • Across five years, Return on Sales topped out at 3.14% in Q3 2025 and bottomed at 20.0% in Q1 2025.